Baillie Gifford Amends Denali Therapeutics Stake (SC 13G/A)
Ticker: DNLI · Form: SC 13G/A · Filed: Jan 30, 2024 · CIK: 1714899
| Field | Detail |
|---|---|
| Company | Denali Therapeutics Inc. (DNLI) |
| Form Type | SC 13G/A |
| Filed Date | Jan 30, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, biotech, fund-activity
TL;DR
**Baillie Gifford updated its Denali Therapeutics stake, watch for ownership percentage details.**
AI Summary
Baillie Gifford & Co, a prominent investment management firm, has filed an Amendment No. 6 to its Schedule 13G for Denali Therapeutics Inc. This filing, dated December 29, 2023, indicates a change in their beneficial ownership of Denali's Common Stock. While the exact percentage change isn't detailed in the provided text, an amendment suggests a notable adjustment to their holdings. This matters to investors because Baillie Gifford is a significant institutional investor, and changes in their position can signal their evolving confidence in Denali's future prospects, potentially influencing other investors' decisions.
Why It Matters
Changes in major institutional ownership can signal shifting sentiment about a company's future, potentially impacting stock price and investor confidence.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of institutional ownership changes and does not inherently indicate high risk.
Analyst Insight
Investors should seek out the full SC 13G/A filing to determine the exact change in Baillie Gifford's beneficial ownership percentage in Denali Therapeutics Inc. to understand the magnitude and direction of their sentiment.
Key Players & Entities
- Baillie Gifford & Co (company) — the investment management firm filing the SC 13G/A
- Denali Therapeutics Inc. (company) — the subject company whose securities are being reported
- December 29, 2023 (date) — the date of the event requiring the filing
- Amendment No. 6 (number) — the specific amendment number to the Schedule 13G
- Common Stock (other) — the class of securities being reported
Forward-Looking Statements
- Baillie Gifford's updated ownership percentage in Denali Therapeutics will be disclosed in the full filing. (Baillie Gifford & Co) — high confidence, target: Immediately upon full filing review
- Other institutional investors may review Baillie Gifford's updated position for insights into Denali Therapeutics. (Denali Therapeutics Inc.) — medium confidence, target: Short-term
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing under the Securities Exchange Act of 1934.
Who is the reporting person in this filing?
The reporting person is BAILLIE GIFFORD & CO, an investment management firm based in Edinburgh, X0.
Which company's securities are the subject of this filing?
The subject company is Denali Therapeutics Inc., a biological products company based in South San Francisco, CA.
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which requires the filing of this statement was December 29, 2023.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Stock of Denali Therapeutics Inc. is 24823R105.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 30, 2024 regarding Denali Therapeutics Inc. (DNLI).